Compare Stocks: ZOM, FENC, RLMD, and TTRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FENC Adherex Technologies	$10.13 -5.5%	$11.27	$5.65 ▼ $13.25	$356.25M	1.23	204,237 shs	124,003 shs
RLMD Relmada Therapeutics	$3.45 -1.9%	$4.28	$1.80 ▼ $8.00	$368.55M	0.51	1.48 million shs	873,272 shs
TTRX Turn Therapeutics	$10.45 -5.9%	$11.50	$2.57 ▼ $16.45	$308.99M	N/A	66,367 shs	57,431 shs
ZOM Zomedica		$0.00	$0.09 ▼ $0.16	$95.35M	1.03	4.72 million shs	790,936 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FENC Adherex Technologies	+0.09%	+0.94%	-2.19%	-3.94%	+25.09%
RLMD Relmada Therapeutics	+3.54%	+0.86%	-22.35%	-43.48%	+72.06%
TTRX Turn Therapeutics	-7.42%	-10.11%	-12.45%	+15.25%	+1,110,999,900.00%
ZOM Zomedica	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FENC Adherex Technologies	$10.13 -5.5%	$11.27	$5.65 ▼ $13.25	$356.25M	1.23	204,237 shs	124,003 shs
RLMD Relmada Therapeutics	$3.45 -1.9%	$4.28	$1.80 ▼ $8.00	$368.55M	0.51	1.48 million shs	873,272 shs
TTRX Turn Therapeutics	$10.45 -5.9%	$11.50	$2.57 ▼ $16.45	$308.99M	N/A	66,367 shs	57,431 shs
ZOM Zomedica		$0.00	$0.09 ▼ $0.16	$95.35M	1.03	4.72 million shs	790,936 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FENC Adherex Technologies	+0.09%	+0.94%	-2.19%	-3.94%	+25.09%
RLMD Relmada Therapeutics	+3.54%	+0.86%	-22.35%	-43.48%	+72.06%
TTRX Turn Therapeutics	-7.42%	-10.11%	-12.45%	+15.25%	+1,110,999,900.00%
ZOM Zomedica	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FENC Adherex Technologies	2.50	Moderate Buy	$17.00	67.80% Upside
RLMD Relmada Therapeutics	2.75	Moderate Buy	$12.00	248.33% Upside
TTRX Turn Therapeutics	2.50	Moderate Buy	$9.00	-13.88% Downside
ZOM Zomedica	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ZOM, FENC, RLMD, and TTRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	TTRX Turn Therapeutics	Lucid Cap Mkts Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
9/14/2026	RLMD Relmada Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/14/2026	TTRX Turn Therapeutics	WBB Securities Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Hold ➝ Sell	$10.00
9/9/2026	FENC Adherex Technologies	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$16.00
8/18/2026	TTRX Turn Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/12/2026	FENC Adherex Technologies	B. Riley Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$16.00 ➝ $18.00
8/12/2026	FENC Adherex Technologies	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$13.00 ➝ $16.00
7/21/2026	TTRX Turn Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold
7/20/2026	TTRX Turn Therapeutics	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
7/17/2026	FENC Adherex Technologies	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
7/13/2026	TTRX Turn Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E) ➝ Sell (D-)

(Data available from 10/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FENC Adherex Technologies	$44.64M	7.97	N/A	N/A	$1.04 per share	9.74
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	$1.18 per share	N/A
TTRX Turn Therapeutics	N/A	N/A	N/A	N/A	$0.16 per share	N/A
ZOM Zomedica	$25.19M	0.00	N/A	N/A	$0.24 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FENC Adherex Technologies	-$9.74M	-$0.13	N/A	10.44	N/A	-6.09%	-5.71%	-2.37%	11/12/2026 (Estimated)
RLMD Relmada Therapeutics	-$57.38M	-$0.90	N/A	N/A	N/A	N/A	-47.52%	-43.97%	11/12/2026 (Estimated)
TTRX Turn Therapeutics	-$3.19M	-$0.29	N/A	N/A	N/A	N/A	-230.84%	-53.19%	N/A
ZOM Zomedica	-$34.53M	-$0.06	N/A	N/A	N/A	-232.88%	-12.47%	-11.84%	N/A

Latest ZOM, FENC, RLMD, and TTRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	FENC Adherex Technologies	$0.02	$0.05	+$0.03	$0.05	$16.21 million	$17.87 million
8/12/2026	Q2 2026	TTRX Turn Therapeutics	N/A	-$0.20	N/A	-$0.20	N/A	N/A
8/6/2026	Q2 2026	RLMD Relmada Therapeutics	-$0.1995	-$0.11	+$0.0895	-$0.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
FENC Adherex Technologies	N/A	N/A	N/A	N/A	N/A
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	N/A
TTRX Turn Therapeutics	N/A	N/A	N/A	N/A	N/A
ZOM Zomedica	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FENC Adherex Technologies	N/A	5.85	5.66
RLMD Relmada Therapeutics	N/A	29.52	29.52
TTRX Turn Therapeutics	8.83	1.19	1.19
ZOM Zomedica	N/A	10.82	10.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FENC Adherex Technologies	55.51%
RLMD Relmada Therapeutics	45.24%
TTRX Turn Therapeutics	N/A
ZOM Zomedica	8.95%

Insider Ownership

Company	Insider Ownership
FENC Adherex Technologies	10.73%
RLMD Relmada Therapeutics	14.50%
TTRX Turn Therapeutics	N/A
ZOM Zomedica	4.19%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FENC Adherex Technologies	35	35.14 million	31.37 million	Optionable
RLMD Relmada Therapeutics	17	106.67 million	91.20 million	Optionable
TTRX Turn Therapeutics	2	29.79 million	N/A	N/A
ZOM Zomedica	50	979.95 million	938.89 million	Not Optionable

ZOM, FENC, RLMD, and TTRX Headlines

Recent News About These Companies

Zomedica Corp. (ZOMDF) Inside Marketing: How Demand Creation Drives Revenue and Supports Distinct Product Portfolios Transcript

September 26, 2026 | seekingalpha.com

Zomedica stringe un accordo con un gruppo veterinario per i suoi prodotti

September 23, 2026 | it.investing.com

Zomedica Announces Strategic Partnership with Veterinary Study Groups (VMG) to Deliver Advanced Veterinary Technologies to Independent Practices

September 22, 2026 | accessnewswire.comA

Zomedica Corp. (ZOMDF) Q2 2026 Earnings Call Transcript

August 28, 2026 | seekingalpha.com

Zomedica collaborates with Boehringer Ingelheim Animal Health Canada to expand equine endocrine diagnostic testing using TRUFORMA platform

August 14, 2026 | pharmabiz.comP

Zomedica Corp.: Zomedica Announces Strategic Collaboration with Boehringer Ingelheim Animal Health Canada Inc. to Expand Equine Endocrine Diagnostic Testing Using TRUFORMA Platform

August 13, 2026 | finanznachrichten.de

ZOMEDICA CORP

July 30, 2026 | finanznachrichten.de

Zomedica Corp. (ZOMDF) Discusses Sales Strategy and Execution in Veterinary Medicine Transcript

July 25, 2026 | seekingalpha.com

Zomedica Corp.: Zomedica Announces "Fourth Friday at Four" Webinar on July 24, 2026: Zomedica's Sales Organization - From Strategy to the Clinic

July 15, 2026 | finanznachrichten.de

Zomedica Corp. (ZOMDF) Discusses Five Pillars Framework for Clinical Value and Shareholder Returns in Veterinary Practice Transcript

June 26, 2026 | seekingalpha.com

Zomedica Corp. (ZOMDF) Q1 2026 Earnings Call Transcript

May 29, 2026 | seekingalpha.com

Zomedica Pharmaceuticals (ZOMDF) SEC Filings

May 23, 2026 | nasdaq.com

Zomedica Corp.: Zomedica Announces "Fifth Friday at Four" Webinar on May 29th: First Quarter 2026 Financial Results and a Deep Dive into the Companion Animal VetTech Market

May 15, 2026 | finanznachrichten.de

Zomedica Corp.: Zomedica Announces Record First Quarter Revenue of $8.8 Million, Reflecting 35% Annual Growth; and $47.5 Million in Liquidity

May 6, 2026 | finanznachrichten.de

Zomedica Corp. (ZOMDF) Discusses Manufacturing Strategy and Quality Operations for Veterinary Diagnostics and Therapeutics Transcript

April 24, 2026 | seekingalpha.com

Zomedica Insider Trading Activity | OTC:ZOMDF | Benzinga

April 7, 2026 | benzinga.com

Zomedica Corp. (ZOMDF) Discusses the Equine Veterinary Market Opportunity Transcript

March 28, 2026 | seekingalpha.com

Zomedica Corp.: Zomedica Announces Strategic Collaboration with Boehringer Ingelheim to Expand Equine Endocrine Diagnostic Testing Using TRUFORMA Platform

March 19, 2026 | finanznachrichten.de

Zomedica Announces Record Fourth Quarter Revenue of $10.5 Million and Full Year Revenue of $32.0 Million for 2025, Reflecting 17% Annual Growth; Achieves 68% Gross Margin and ...

March 16, 2026 | pharmiweb.comP

Zomedica Corp.: Zomedica to Review 2025 Financial Results and Highlight Equine Market Opportunity During March 27th "Fourth Friday at Four" Investor Webinar

March 10, 2026 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZOM, FENC, RLMD, and TTRX Company Descriptions

Adherex Technologies NASDAQ:FENC

$10.13 -0.59 (-5.49%)

As of 03:24 PM Eastern

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

Relmada Therapeutics NASDAQ:RLMD

$3.44 -0.07 (-1.85%)

As of 03:23 PM Eastern

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

Turn Therapeutics NASDAQ:TTRX

$10.45 -0.66 (-5.94%)

As of 03:23 PM Eastern

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events. Our proprietary platform has been validated across multiple FDA-cleared medical devices. Our primary development programs focus on dermatological diseases, including moderate to severe eczema and onychomycosis. Our company’s origin is rooted in the personal journey of our founder, who developed a topical ointment to heal his own chronic, treatment-resistant wounds using the PermaFusion platform he developed. His initial formulation, now known as Hexagen (“Hexagen”) suspends certain antimicrobial/anti-inflammatory compounds in petrolatum without known cytotoxicity, irritation or sensitization. This formula has received three FDA clearances and has been utilized extensively in humans, which we believe demonstrates both technical proof of concept and meaningful therapeutic effects. The formula also has been demonstrated to provide anti-inflammatory immunological signaling (IL 36, IL 31, IL 4 inhibition), in-vivo nail penetration with fungal pathogen elimination, and other potential therapeutic benefits. These products are not presently on the market, and we are not currently generating revenue from these devices, as we focus on drug development of our core technology. In addition to our dermatology and wound programs, we are exploring broader applications of our PermaFusion technology. In partnership with a leading global nonprofit organization, we are attempting to develop intranasal vaccines with sufficient thermostability to withstand distribution without deep-freeze. Our goal is to eliminate the need for frozen storage and, thus, enable deployment and delivery to low-resource settings that do not maintain suitable cold storage infrastructure required for administration of modern-day vaccines. Furthermore, if we are successful in this initial program, we believe there may be opportunities to develop additional vaccines in thermostable, intranasal form. By reducing cold-storage infrastructure requirements and therefore enabling standard shipping of such vaccines, we believe intranasal vaccines have the potential to enhance patient uptake by enabling immunization in a broader variety of settings including in clinic, hospital and home-health settings. We believe this initiative highlights our platform’s versatility and its potential to unlock new therapeutic categories beyond dermatology. We have also completed preclinical, in-vivo xenograft studies for herpes zoster ophthalmicus (shingles of the eye) and basal cell carcinoma. A mildly reformulated version of the Hexagen formula was employed for the ocular study and compared this reformulation with placebo as a topical ocular agent intended to reduce viral load of herpes zoster in an animal model. Results obtained showed an 85% reduction in viral load compared to placebo without adverse events. For the basal cell carcinoma xenograft study, the Hexagen formula was compared to both placebo and 5-Fluorouracil (standard of care topical chemotherapy) as a topical treatment intended to reduce basal cell tumor size. The Hexagen formula showed an approximate 29% comparative reduction in tumor size to the placebo and an approximate 20% comparative reduction in tumor size compared to 5-Fluorouracil. We believe these preclinical in-vivo studies suggest meaningful potential in these indications, which we may continue to explore at the conclusion of our lead drug programs. We believe such exploratory results further underscore the potential breadth of opportunity enabled by our platform. We were initially formed on January 6, 2015, as Global Health Solutions, LLC, a Delaware limited liability company. On October 12, 2018, Global Health Solutions, LLC converted to a Delaware corporation under the name Global Health Solutions, Inc., dba Turn Therapeutics. Immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, we intend to change our name to Turn Therapeutics Inc. Our principal executive offices are located in Westlake Village, CA.

Zomedica NYSEAMERICAN:ZOM

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZOM, FENC, RLMD, and TTRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZOM, FENC, RLMD, and TTRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZOM, FENC, RLMD, and TTRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZOM, FENC, RLMD, and TTRX Company Descriptions

Adherex Technologies NASDAQ:FENC

Relmada Therapeutics NASDAQ:RLMD

Turn Therapeutics NASDAQ:TTRX

Zomedica NYSEAMERICAN:ZOM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZOM, FENC, RLMD, and TTRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZOM, FENC, RLMD, and TTRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZOM, FENC, RLMD, and TTRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZOM, FENC, RLMD, and TTRX Company Descriptions

Adherex Technologies NASDAQ:FENC

Relmada Therapeutics NASDAQ:RLMD

Turn Therapeutics NASDAQ:TTRX

Zomedica NYSEAMERICAN:ZOM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools